Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic.
Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic.
复制标题
胰腺癌的分子分型：将基因组学和转录组学转化为临床
DOI：
10.7150/jca.17622
复制
发表时间：
2017
影响因子：
3.9
通讯作者：
Zhao Y
中科院分区：
文献类型：
--
作者：
Du Y;Zhao B;Liu Z;Ren X;Zhao W;Li Z;You L;Zhao Y
胰腺癌仍然是最致命的恶性肿瘤之一，迫切需要对这种疾病进行个性化诊断和干预。测序技术的快速发展使得一系列胰腺癌的遗传和表观遗传学测序研究相继完成。胰腺癌的突变景观通常被描述为体细胞突变、结构变异、表观遗传改变和核心信号通路。近年来，根据转录因子和下游靶点的表达或结构重排的分布，提出了四种重要的胰腺癌分子亚型分类。越来越多的研究集中在鉴定驱动胰腺癌的体细胞突变和其他遗传畸变上，这导致了基于分子分型的精准医学的新时代。然而，很少有已知的分子分类用于指导临床策略。在基因组学和转录组学的发现能够转化为临床之前，必须克服具体的科学、监管和伦理挑战。
Pancreatic cancer remains one of the most lethal malignancies, and insights into both personalized diagnosis and intervention of this disease are urgently needed. The rapid development of sequencing technologies has enabled the successive completion of a series of genetic and epigenetic sequencing studies of pancreatic cancer. The mutational landscape of pancreatic cancer is generally portrayed in terms of somatic mutations, structural variations, epigenetic alterations and the core signaling pathways. In recent years, four significant molecular subtype classifications of pancreatic cancer have been proposed based on the expression of transcription factors and downstream targets or the distribution of structural rearrangements. Increasing researches focus on the identification of somatic mutations and other genetic aberrations that drive pancreatic cancer has led to a new era of precision medicine based on molecular subtyping. However, few known molecular classifications are used to guide clinical strategies. Specific scientific, regulatory and ethical challenges must be overcome before genomic and transcriptomic discoveries can be translated into the clinic.